AU2009307783A1 - Imaging and radiotherapy methods - Google Patents

Imaging and radiotherapy methods Download PDF

Info

Publication number
AU2009307783A1
AU2009307783A1 AU2009307783A AU2009307783A AU2009307783A1 AU 2009307783 A1 AU2009307783 A1 AU 2009307783A1 AU 2009307783 A AU2009307783 A AU 2009307783A AU 2009307783 A AU2009307783 A AU 2009307783A AU 2009307783 A1 AU2009307783 A1 AU 2009307783A1
Authority
AU
Australia
Prior art keywords
alkyl
formula
compound
fluoro
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009307783A
Other languages
English (en)
Inventor
Rajiv Bhalla
Alan Cuthbertson
Peter Brian Iveson
Vijaya Raj Kuniyil Kulangara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
General Electric Co
Original Assignee
GE Healthcare Ltd
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd, General Electric Co filed Critical GE Healthcare Ltd
Publication of AU2009307783A1 publication Critical patent/AU2009307783A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
AU2009307783A 2008-10-21 2009-10-20 Imaging and radiotherapy methods Abandoned AU2009307783A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10700108P 2008-10-21 2008-10-21
US61/107,001 2008-10-21
GB0819280.9 2008-10-21
GBGB0819280.9A GB0819280D0 (en) 2008-10-21 2008-10-21 Imgaing and radiotherapy methods
PCT/US2009/061271 WO2010048144A2 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods

Publications (1)

Publication Number Publication Date
AU2009307783A1 true AU2009307783A1 (en) 2010-04-29

Family

ID=40097766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009307783A Abandoned AU2009307783A1 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods

Country Status (12)

Country Link
US (1) US20110286922A1 (enExample)
EP (1) EP2349351A2 (enExample)
JP (1) JP2012506439A (enExample)
KR (1) KR20110074988A (enExample)
CN (1) CN102186505A (enExample)
AU (1) AU2009307783A1 (enExample)
BR (1) BRPI0919690A2 (enExample)
CA (1) CA2738955A1 (enExample)
GB (1) GB0819280D0 (enExample)
MX (1) MX2011004161A (enExample)
RU (1) RU2011113996A (enExample)
WO (1) WO2010048144A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
AU2005219412A1 (en) 2004-03-02 2005-09-15 Cellectar, Inc. Phospholipid analogs for diagnosis and treatment of cancer
CU23844B1 (es) * 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
JP6092624B2 (ja) * 2009-06-12 2017-03-08 セレクター，インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
JP2013515083A (ja) * 2009-12-22 2013-05-02 ジーイー・ヘルスケア・リミテッド 癌幹細胞におけるａｌｄｈのインビボイメージング用アルデヒド
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2013012754A1 (en) * 2011-07-15 2013-01-24 University Of Southern California Boron-based dual imaging probes, compositions and methods for rapid aqueous f-18 labeling, and imaging methods using same
WO2013048832A1 (en) * 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) * 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
US8927732B2 (en) * 2012-03-30 2015-01-06 General Electric Company Biotin stannane for HPLC-free radioiodination
US20160008493A1 (en) * 2013-03-15 2016-01-14 The Johns Hopkins University Radioactive substrates for aldehyde dehydrogenase
CN109073556A (zh) * 2016-04-28 2018-12-21 国立大学法人名古屋大学 荧光探针、荧光检测方法及荧光探针的使用方法
FR3054564B1 (fr) * 2016-07-28 2018-08-31 Advanced Biodesign Substrat specifique d'une isoenzyme de l'aldh
KR101941223B1 (ko) * 2017-04-04 2019-01-22 을지대학교 산학협력단 복강경 수술용 삼중 융합영상장치
JP2023025307A (ja) * 2020-01-31 2023-02-22 国立大学法人 東京大学 アルデヒドロゲナーゼ１ａ１検出用青色蛍光プローブ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876956A (en) * 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US20040009956A1 (en) * 2002-04-29 2004-01-15 Dehua Pei Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0502277D0 (en) * 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
EP1996182A4 (en) * 2006-02-27 2009-08-12 Univ Johns Hopkins CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS
WO2008036419A2 (en) * 2006-09-22 2008-03-27 The Regents Of The University Of Michigan Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker

Also Published As

Publication number Publication date
GB0819280D0 (en) 2008-11-26
KR20110074988A (ko) 2011-07-05
WO2010048144A3 (en) 2010-07-22
MX2011004161A (es) 2011-06-06
JP2012506439A (ja) 2012-03-15
RU2011113996A (ru) 2012-11-27
BRPI0919690A2 (pt) 2015-12-08
US20110286922A1 (en) 2011-11-24
CN102186505A (zh) 2011-09-14
EP2349351A2 (en) 2011-08-03
CA2738955A1 (en) 2010-04-29
WO2010048144A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
AU2009307783A1 (en) Imaging and radiotherapy methods
US20120244074A1 (en) Labelled integrin binders
EP2305316A2 (en) Diphosphorylated glycopeptide imaging agent for fibrosis
JP5709841B2 (ja) 標識分子イメージング剤、製造方法及び使用方法
US20090220420A1 (en) Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (pbr)
US11844846B2 (en) Styrylbenzothiazole derivatives and uses in imaging methods
US20080292547A1 (en) Novel Imaging Agents for Fibrosis
US20090317328A1 (en) Tricyclic oxazepines as in vivo imaging compounds
US20120003154A1 (en) Aryloxyanilide derivatives
WO2014122228A1 (en) Labelled compounds that bind to alpha-v-beta-3 integrin
WO2013048832A1 (en) 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
US20150320892A1 (en) Imaging fibrosis
US20100247435A1 (en) Measurement of neural activity
WO2013048811A1 (en) Imaging and radiotherapy methods for tumour stem cells
WO2008003954A1 (en) Dye imaging agents
US20130101509A1 (en) Imaging and radiotherapy methods
US20110027178A1 (en) Imaging the central nervous system
US20080279771A1 (en) Novel Imaging Agents for Cancer
JP2011528014A (ja) 治療のモニタリング

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application